temozolomide has been researched along with tpi-287 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashikaga, T; Bergendahl, G; DeSarno, M; Eslin, D; Ferguson, W; Hanna, GK; Higgins, T; Kaplan, J; Kraveka, J; Mitchell, D; Roberts, W; Sholler, GL; Werff, AV | 1 |
| Amaria, RN; Bassett, RL; Bedikian, AY; Cain, S; Davies, MA; Hwu, P; Hwu, WJ; Lecagoonporn, S; McQuade, JL; Patel, SP; Posada, LP | 1 |
2 trial(s) available for temozolomide and tpi-287
| Article | Year |
|---|---|
A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dacarbazine; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Taxoids; Temozolomide | 2016 |
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Taxoids; Temozolomide | 2016 |